| Oct 31 |
Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
|
| Oct 24 |
Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium
|
| Oct 23 |
Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium
|
| Oct 7 |
Palatin receives notice of non-compliance from NYSE American
|
| Oct 7 |
Palatin Receives Notice of Non-Compliance from NYSE American
|
| Oct 2 |
Q4 2024 Palatin Technologies Inc Earnings Call
|
| Oct 2 |
Palatin Technologies Inc (PTN) Q4 2024 Earnings Call Transcript Highlights: Strategic Moves and ...
|
| Oct 1 |
Palatin Technologies, Inc. (PTN) Q4 2024 Earnings Call Transcript
|
| Oct 1 |
Palatin Technologies GAAP EPS of -$0.51
|
| Oct 1 |
Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
|
